ADAC posts record fourth quarter
ADAC Laboratories continues to experience healthy financial growth, thanks to robust performances from all of its businesses. The Milpitas, CA-based nuclear medicine and radiation therapy powerhouse posted a 20% increase in revenue during its record
ADAC Laboratories continues to experience healthy financial growth, thanks to robust performances from all of its businesses. The Milpitas, CA-based nuclear medicine and radiation therapy powerhouse posted a 20% increase in revenue during its record fourth quarter and a 15% revenue increase for its fiscal year.
For the period (end-September), ADAC had record revenues of $86.9 million, compared with the $72.5 million reported in the same period last year. Excluding a one-time restructuring charge, net income was $8.2 million, compared with the $6 million reported last year. With the charge, net income was $3.7 million.
ADAC was also pleased with the progress of its PET business during the quarter. During the period, the company shipped 18 Molecular Coincidence Detection (MCD) units and two C-PET units, compared with 13 MCD units and one C-PET in the prior quarter.
For the fiscal year, ADAC reported revenues of $323.4 million, compared with the $282.3 million reported for the previous fiscal year. Excluding one-time charges, ADAC had net income of $29 million. Including one-time charges, net income for fiscal 1998 was $14.5 million.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
